Treatments administered for 52 weeks included placebo eye drops instilled 4 times daily ( n = 73 ) ; pazopanib 5 mg/ml instilled 3 ( n = 72 ) or 4 times daily ( n = 74 ) ; pazopanib 10 mg/ml instilled 2 ( n = 73 ) , 3 ( n = 73 ) , or 4 times daily ( n = 72 ) ; or ranibizumab injection administered once every 4 weeks ( n = 73 ) .